Skye Bioscience, Inc. (SKYE)
Automate Your Wheel Strategy on SKYE
With Tiblio's Option Bot, you can configure your own wheel strategy including SKYE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SKYE
- Rev/Share 0.0
- Book/Share 1.1013
- PB 3.1871
- Debt/Equity 0.0084
- CurrentRatio 6.0857
- ROIC -1.1397
- MktCap 108769284.0
- FreeCF/Share -0.8811
- PFCF -3.1128
- PE -3.2853
- Debt/Assets 0.007
- DivYield 0
- ROE -0.6865
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SKYE | William Blair | -- | Outperform | -- | -- | Feb. 28, 2025 |
| Initiation | SKYE | Scotiabank | -- | Sector Outperform | -- | $20 | Sept. 30, 2024 |
| Initiation | SKYE | JMP Securities | -- | Mkt Outperform | -- | $15 | Sept. 10, 2024 |
News
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day.
Read More
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. The presentations are accessible at the following link.
Read More
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Read More
About Skye Bioscience, Inc. (SKYE)
- IPO Date 2014-11-26
- Website https://skyebioscience.com
- Industry Biotechnology
- CEO Punit S. Dhillon
- Employees 16